Roivant Sciences Ltd (ROIV)

$34.91 +0.40 (1.16%)
Market Cap 24.82B
Revenue (ttm) 8.26M
Net Income (ttm) -299.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,629.18%
Debt to Equity Ratio 0.00
Volume 4,052,800
Avg Vol 6,164,420
Day's Range N/A - N/A
Shares Out 719.27M
Stochastic %K 23%
Beta 1.11
Analysts Strong Sell
Price Target $39.04

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7400 3347
Website: roivant.com
Address:
50 Broadway, 7th Floor, London, United Kingdom
CapitalismUSA
CapitalismUSA Jul. 10 at 12:19 PM
$ABUS $ROIV How about a 1:1 stock swap acquisition? $37 No “Friends & Family Discounts” Androwski
1 · Reply
DocPharm
DocPharm Jul. 10 at 11:19 AM
$ROIV this one too ❤️
0 · Reply
Joe_Mama
Joe_Mama Jul. 10 at 2:57 AM
$ROIV Magnet to $40 🧲
1 · Reply
DocPharm
DocPharm Jul. 9 at 8:44 PM
$ROIV BioNtech & Genevant combination 🤔
0 · Reply
Alfalcon
Alfalcon Jul. 9 at 7:03 PM
$ROIV Time for analyst to revise PT again
1 · Reply
Baseballmom94
Baseballmom94 Jul. 7 at 6:31 PM
$ABUS $MRNA $ROIV
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 7 at 6:28 PM
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week $ABUS $ROIV $MRNA https://stocktwits.com/news/equity/markets/abus-stock-rallies-ahead-of-big-payout-from-moderna-settlement-this-week/cZmlrrOR7ZK
0 · Reply
WAJeff
WAJeff Jul. 6 at 1:26 AM
$ROIV 35.99 ath
0 · Reply
mj6534
mj6534 Jul. 3 at 12:05 AM
$ABUS $MRNA $ROIV Criminal how dirty these two companies are. That should be us up 400-1000% insane how us shareholders were finagled and screwed over.
2 · Reply
Biibrian
Biibrian Jul. 1 at 12:20 AM
$ABUS $4.98 and has broken out of triangle. Short interest is 20% yet remember 25% is $ROIV and 15% $MS. so basically short interest of real float is much smaller in the event any positive news.
0 · Reply
Latest News on ROIV
Roivant Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:20 AM EDT - 5 weeks ago

Roivant Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Roivant Sciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 5 weeks ago

Roivant Sciences Transcript: Jefferies Global Healthcare Conference 2026

Roivant Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 29, 2026, 8:00 AM EDT - 6 weeks ago

Roivant Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Roivant Sciences price target raised to $40 from $35 at JPMorgan

2026-05-26T17:58:08.000Z - 7 weeks ago

Roivant Sciences price target raised to $40 from $35 at JPMorgan

Roivant Sciences price target raised to $36 from $30 at Guggenheim

2026-05-26T11:09:13.000Z - 7 weeks ago

Roivant Sciences price target raised to $36 from $30 at Guggenheim

Roivant Sciences price target raised to $31.50 from $29.50 at BofA

2026-05-25T09:00:55.000Z - 7 weeks ago

Roivant Sciences price target raised to $31.50 from $29.50 at BofA

Roivant Sciences price target raised to $41 from $38 at TD Cowen

2026-05-21T12:37:28.000Z - 7 weeks ago

Roivant Sciences price target raised to $41 from $38 at TD Cowen

Roivant Sciences price target raised to $42 from $35 at Citi

2026-05-21T11:03:04.000Z - 7 weeks ago

Roivant Sciences price target raised to $42 from $35 at Citi

Roivant Sciences rises 15.2%

2026-05-20T16:05:53.000Z - 7 weeks ago

Roivant Sciences rises 15.2%

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

May 20, 2026, 11:38 AM EDT - 7 weeks ago

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

IMVT

Roivant Sciences rises 11.7%

2026-05-20T14:08:44.000Z - 7 weeks ago

Roivant Sciences rises 11.7%

Roivant Sciences Earnings Call Transcript: Q4 2026

May 20, 2026, 8:00 AM EDT - 7 weeks ago

Roivant Sciences Earnings Call Transcript: Q4 2026

Roivant Sciences Annual report: Q4 2026

May 20, 2026, 8:00 AM EDT - 7 weeks ago

Roivant Sciences Annual report: Q4 2026

Roivant Sciences Slides: Q4 2026

May 20, 2026, 8:00 AM EDT - 7 weeks ago

Roivant Sciences Slides: Q4 2026

Roivant Sciences Earnings release: Q4 2026

May 20, 2026, 8:00 AM EDT - 7 weeks ago

Roivant Sciences Earnings release: Q4 2026

Roivant Sciences reports Q4 EPS 28c, consensus (35c)

2026-05-20T11:10:39.000Z - 7 weeks ago

Roivant Sciences reports Q4 EPS 28c, consensus (35c)

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

May 20, 2026, 7:00 AM EDT - 7 weeks ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant Sciences price target raised to $29.50 from $29 at BofA

2026-05-14T12:20:11.000Z - 2 months ago

Roivant Sciences price target raised to $29.50 from $29 at BofA

Roivant Sciences Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 1:00 PM EDT - 2 months ago

Roivant Sciences Transcript: Bank of America Global Healthcare Conference 2026

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

May 11, 2026, 4:05 PM EDT - 2 months ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

May 11, 2026, 4:05 PM EDT - 2 months ago

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Roivant Sciences participates in a conference call with JPMorgan

2026-04-22T16:03:31.000Z - 2 months ago

Roivant Sciences participates in a conference call with JPMorgan

Roivant Sciences assumed with an Overweight at Piper Sandler

2026-04-16T14:07:55.000Z - 3 months ago

Roivant Sciences assumed with an Overweight at Piper Sandler

Roivant Sciences price target raised to $34 from $30 at Jefferies

2026-04-07T14:34:13.000Z - 3 months ago

Roivant Sciences price target raised to $34 from $30 at Jefferies

ABUS MRNA

Roivant Sciences Transcript: Study result

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Roivant Sciences Transcript: Study result

Roivant Sciences Press release: Study result

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Roivant Sciences Press release: Study result

Roivant Sciences Slides: Study result

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Roivant Sciences Slides: Study result

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Apr 2, 2026, 5:00 AM EDT - 3 months ago

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Apr 2, 2026, 5:00 AM EDT - 3 months ago

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Mar 28, 2026, 3:00 PM EDT - 3 months ago

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Bernstein bullish on Roivant Sciences, initiates with an Outperform

2026-03-20T12:50:45.000Z - 4 months ago

Bernstein bullish on Roivant Sciences, initiates with an Outperform

Roivant Sciences initiated with an Outperform at Bernstein

2026-03-19T20:22:56.000Z - 4 months ago

Roivant Sciences initiated with an Outperform at Bernstein

Roivant Sciences Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 8:40 AM EDT - 4 months ago

Roivant Sciences Transcript: Leerink Global Healthcare Conference 2026

Roivant Sciences price target raised to $33 from $31 at JPMorgan

2026-03-05T11:16:18.000Z - 4 months ago

Roivant Sciences price target raised to $33 from $31 at JPMorgan

Roivant Sciences Transcript: Status update

Mar 3, 2026, 4:45 PM EST - 4 months ago

Roivant Sciences Transcript: Status update

Roivant Sciences Press release: Status update

Mar 3, 2026, 4:45 PM EST - 4 months ago

Roivant Sciences Press release: Status update

Roivant Sciences Slides: Status update

Mar 3, 2026, 4:45 PM EST - 4 months ago

Roivant Sciences Slides: Status update

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Mar 3, 2026, 4:26 PM EST - 4 months ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

MRNA ABUS

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 4 months ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ABUS MRNA

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 4 months ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ABUS MRNA

Roivant Sciences Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:50 AM EST - 4 months ago

Roivant Sciences Transcript: TD Cowen 46th Annual Health Care Conference

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

Mar 3, 2026, 7:00 AM EST - 4 months ago

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

Roivant Sciences Earnings Call Transcript: Q3 2026

Feb 6, 2026, 8:00 AM EST - 5 months ago

Roivant Sciences Earnings Call Transcript: Q3 2026

Roivant Sciences Quarterly report: Q3 2026

Feb 6, 2026, 8:00 AM EST - 5 months ago

Roivant Sciences Quarterly report: Q3 2026

Roivant Sciences Earnings release: Q3 2026

Feb 6, 2026, 8:00 AM EST - 5 months ago

Roivant Sciences Earnings release: Q3 2026

Roivant Sciences Slides: Q3 2026

Feb 6, 2026, 8:00 AM EST - 5 months ago

Roivant Sciences Slides: Q3 2026

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Feb 6, 2026, 7:00 AM EST - 5 months ago

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

Feb 6, 2026, 7:00 AM EST - 5 months ago

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

Feb 6, 2026, 7:00 AM EST - 5 months ago

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Jan 23, 2026, 4:15 PM EST - 6 months ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Roivant Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:00 PM EST - 6 months ago

Roivant Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Roivant Sciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:00 PM EST - 6 months ago

Roivant Sciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Roivant Sciences Transcript: Investor Day 2025

Dec 11, 2025, 8:00 AM EST - 7 months ago

Roivant Sciences Transcript: Investor Day 2025

Roivant Sciences Slides: FY 2025

Dec 11, 2025, 8:00 AM EST - 7 months ago

Roivant Sciences Slides: FY 2025

Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day

Dec 11, 2025, 7:30 AM EST - 7 months ago

Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day

Roivant Sciences Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 12:00 PM EST - 8 months ago

Roivant Sciences Transcript: Jefferies London Healthcare Conference 2025

Roivant Sciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 8:00 AM EST - 8 months ago

Roivant Sciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Roivant Sciences Slides: Corporate Presentation

Nov 10, 2025, 6:00 PM EST - 8 months ago

Roivant Sciences Slides: Corporate Presentation

Roivant Sciences Earnings Call Transcript: Q2 2026

Nov 10, 2025, 8:00 AM EST - 8 months ago

Roivant Sciences Earnings Call Transcript: Q2 2026

Roivant Sciences Quarterly report: Q2 2026

Nov 10, 2025, 8:00 AM EST - 8 months ago

Roivant Sciences Quarterly report: Q2 2026

Roivant Sciences Earnings release: Q2 2026

Nov 10, 2025, 8:00 AM EST - 8 months ago

Roivant Sciences Earnings release: Q2 2026

Roivant Sciences Slides: Q2 2026

Nov 10, 2025, 8:00 AM EST - 8 months ago

Roivant Sciences Slides: Q2 2026

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Nov 10, 2025, 7:00 AM EST - 8 months ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Oct 27, 2025, 4:10 PM EDT - 9 months ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

IMVT

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Oct 27, 2025, 4:10 PM EDT - 9 months ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Roivant Sciences Transcript: Bank of America Global Healthcare Conference 2025

Sep 24, 2025, 5:45 AM EDT - 10 months ago

Roivant Sciences Transcript: Bank of America Global Healthcare Conference 2025

Roivant Sciences Transcript: Bernstein 2nd Annual Global Healthcare Conference

Sep 23, 2025, 2:00 PM EDT - 10 months ago

Roivant Sciences Transcript: Bernstein 2nd Annual Global Healthcare Conference

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial

Sep 17, 2025, 8:21 AM EDT - 10 months ago

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial

Roivant Sciences Transcript: Study Result

Sep 17, 2025, 8:00 AM EDT - 10 months ago

Roivant Sciences Transcript: Study Result

Roivant Sciences Press release: Study Result

Sep 17, 2025, 8:00 AM EDT - 10 months ago

Roivant Sciences Press release: Study Result

Roivant Sciences Slides: Study Result

Sep 17, 2025, 8:00 AM EDT - 10 months ago

Roivant Sciences Slides: Study Result

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Sep 17, 2025, 7:00 AM EDT - 10 months ago

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Sep 11, 2025, 4:30 PM EDT - 10 months ago

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Sep 4, 2025, 7:00 AM EDT - 11 months ago

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Roivant Sciences Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 11 months ago

Roivant Sciences Transcript: Study Update

Roivant Sciences Press release: Study Update

Sep 3, 2025, 4:30 PM EDT - 11 months ago

Roivant Sciences Press release: Study Update

Roivant Sciences Slides: Study Update

Sep 3, 2025, 4:30 PM EDT - 11 months ago

Roivant Sciences Slides: Study Update

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Sep 3, 2025, 1:01 PM EDT - 11 months ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Roivant Sciences Earnings Call Transcript: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings Call Transcript: Q1 2026

Roivant Sciences Quarterly report: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Quarterly report: Q1 2026

Roivant Sciences Earnings release: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings release: Q1 2026

Roivant Sciences Slides: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Slides: Q1 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Roivant Sciences Proxy statement: Proxy Filing

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Proxy statement: Proxy Filing

Roivant Sciences Proxy statement: Proxy Filing

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Proxy statement: Proxy Filing

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Jul 28, 2025, 4:05 PM EDT - 1 year ago

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Roivant Sciences Transcript: Status Update

Jun 17, 2025, 1:00 PM EDT - 1 year ago

Roivant Sciences Transcript: Status Update

Roivant Sciences Slides: Status Update

Jun 17, 2025, 1:00 PM EDT - 1 year ago

Roivant Sciences Slides: Status Update

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Roivant Sciences Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 4:00 PM EDT - 1 year ago

Roivant Sciences Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

Jun 9, 2025, 4:05 PM EDT - 1 year ago

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

Roivant Sciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 4:20 PM EDT - 1 year ago

Roivant Sciences Transcript: Jefferies Global Healthcare Conference 2025

Roivant Sciences Earnings Call Transcript: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings Call Transcript: Q4 2025

Roivant Sciences Annual report: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Annual report: Q4 2025

Roivant Sciences Earnings release: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings release: Q4 2025

Roivant Sciences Slides: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Slides: Q4 2025

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 29, 2025, 7:00 AM EDT - 1 year ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

May 15, 2025, 4:10 PM EDT - 1 year ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Roivant Sciences Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 7:20 PM EDT - 1 year ago

Roivant Sciences Transcript: BofA Securities 2025 Healthcare Conference

Roivant Sciences Transcript: Status Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Transcript: Status Update

Roivant Sciences Press release: Status Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Press release: Status Update

Roivant Sciences Slides: Status Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Slides: Status Update

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Apr 21, 2025, 7:00 AM EDT - 1 year ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 19, 2025, 7:45 AM EDT - 1 year ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 18, 2025, 4:32 PM EDT - 1 year ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Roivant Sciences Transcript: Leerink’s Global Healthcare Conference 2025

Mar 10, 2025, 10:40 AM EDT - 1 year ago

Roivant Sciences Transcript: Leerink’s Global Healthcare Conference 2025

Roivant Sciences Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 1:10 PM EST - 1 year ago

Roivant Sciences Transcript: TD Cowen 45th Annual Healthcare Conference

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

Roivant Sciences Earnings Call Transcript: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings Call Transcript: Q3 2025

Roivant Sciences Quarterly report: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Quarterly report: Q3 2025

Roivant Sciences Earnings release: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings release: Q3 2025

Roivant Sciences Slides: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Slides: Q3 2025

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Feb 10, 2025, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Roivant Sciences Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 3:00 PM EST - 1 year ago

Roivant Sciences Transcript: Guggenheim SMID Cap Biotech Conference

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Feb 3, 2025, 7:00 AM EST - 1 year ago

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Jan 29, 2025, 4:05 PM EST - 1 year ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Roivant Sciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 5:15 PM EST - 1 year ago

Roivant Sciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Roivant Sciences Slides: FY 2025

Jan 13, 2025, 5:15 PM EST - 1 year ago

Roivant Sciences Slides: FY 2025

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Jan 13, 2025, 9:00 AM EST - 1 year ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Roivant Sciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 4, 2024, 2:10 PM EST - 1 year ago

Roivant Sciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Roivant's lung disease drug fails mid-stage trial

Dec 3, 2024, 7:19 AM EST - 1 year ago

Roivant's lung disease drug fails mid-stage trial

Roivant Sciences Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:00 AM EST - 1 year ago

Roivant Sciences Transcript: Jefferies London Healthcare Conference 2024

Roivant Sciences Earnings Call Transcript: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings Call Transcript: Q2 2025

Roivant Sciences Quarterly report: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Quarterly report: Q2 2025

Roivant Sciences Earnings release: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings release: Q2 2025

Roivant Sciences Slides: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Slides: Q2 2025

Roivant Sciences Transcript: Guggenheim Global Healthcare Conference

Nov 11, 2024, 4:00 PM EST - 1 year ago

Roivant Sciences Transcript: Guggenheim Global Healthcare Conference

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Oct 29, 2024, 4:35 PM EDT - 1 year ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Roivant Flips a Skin Drug to Organon

Sep 18, 2024, 10:59 AM EDT - 1 year ago

Roivant Flips a Skin Drug to Organon

OGN

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Sep 18, 2024, 7:30 AM EDT - 1 year ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

OGN

Roivant Sciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 1:55 PM EDT - 1 year ago

Roivant Sciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Roivant Sciences Transcript: Study Update

Sep 10, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Transcript: Study Update

Roivant Sciences Press release: Study Update

Sep 10, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Press release: Study Update

Roivant Sciences Slides: Study Update

Sep 10, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Slides: Study Update

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

Sep 10, 2024, 6:30 AM EDT - 2 years ago

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Sep 10, 2024, 6:30 AM EDT - 2 years ago

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Roivant Provides Update on Graves' Disease Development Program

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Roivant Provides Update on Graves' Disease Development Program

Roivant Sciences Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 9:15 AM EDT - 2 years ago

Roivant Sciences Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Roivant Sciences Earnings Call Transcript: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings Call Transcript: Q1 2025

Roivant Sciences Quarterly report: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Quarterly report: Q1 2025

Roivant Sciences Earnings release: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings release: Q1 2025

Roivant Sciences Slides: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Slides: Q1 2025

Roivant Sciences Proxy statement: Proxy Filing

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Proxy statement: Proxy Filing

Roivant Sciences Proxy statement: Proxy Filing

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Proxy statement: Proxy Filing

Roivant Sciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 8:40 AM EDT - 2 years ago

Roivant Sciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Roivant Sciences Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 11:30 AM EDT - 2 years ago

Roivant Sciences Transcript: Jefferies 2024 Global Healthcare Conference

Roivant Sciences Earnings Call Transcript: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings Call Transcript: Q4 2024

Roivant Sciences Annual report: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Annual report: Q4 2024

Roivant Sciences Earnings release: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings release: Q4 2024

Roivant Sciences Slides: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Slides: Q4 2024

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 30, 2024, 7:00 AM EDT - 2 years ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

Roivant Sciences Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 9:00 AM EDT - 2 years ago

Roivant Sciences Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

May 16, 2024, 4:05 PM EDT - 2 years ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis

Roivant Sciences Transcript: Status Update

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Transcript: Status Update

Roivant Sciences Slides: Status Update

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Slides: Status Update

Roivant's anti-inflammatory drug succeeds in mid-stage study

Apr 2, 2024, 7:28 AM EDT - 2 years ago

Roivant's anti-inflammatory drug succeeds in mid-stage study

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

CapitalismUSA
CapitalismUSA Jul. 10 at 12:19 PM
$ABUS $ROIV How about a 1:1 stock swap acquisition? $37 No “Friends & Family Discounts” Androwski
1 · Reply
DocPharm
DocPharm Jul. 10 at 11:19 AM
$ROIV this one too ❤️
0 · Reply
Joe_Mama
Joe_Mama Jul. 10 at 2:57 AM
$ROIV Magnet to $40 🧲
1 · Reply
DocPharm
DocPharm Jul. 9 at 8:44 PM
$ROIV BioNtech & Genevant combination 🤔
0 · Reply
Alfalcon
Alfalcon Jul. 9 at 7:03 PM
$ROIV Time for analyst to revise PT again
1 · Reply
Baseballmom94
Baseballmom94 Jul. 7 at 6:31 PM
$ABUS $MRNA $ROIV
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 7 at 6:28 PM
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week $ABUS $ROIV $MRNA https://stocktwits.com/news/equity/markets/abus-stock-rallies-ahead-of-big-payout-from-moderna-settlement-this-week/cZmlrrOR7ZK
0 · Reply
WAJeff
WAJeff Jul. 6 at 1:26 AM
$ROIV 35.99 ath
0 · Reply
mj6534
mj6534 Jul. 3 at 12:05 AM
$ABUS $MRNA $ROIV Criminal how dirty these two companies are. That should be us up 400-1000% insane how us shareholders were finagled and screwed over.
2 · Reply
Biibrian
Biibrian Jul. 1 at 12:20 AM
$ABUS $4.98 and has broken out of triangle. Short interest is 20% yet remember 25% is $ROIV and 15% $MS. so basically short interest of real float is much smaller in the event any positive news.
0 · Reply
mj6534
mj6534 Jun. 26 at 2:48 PM
$ABUS $MRNA up massive today and we are basically the same lol. Androski and the $ROIV board really screwed us. Depending on news in coming months I will Absolutely be happy to join in on class action. How do we go for 5 bil escrow to suddenly settling for 1/5 of that basically. Idk man. Not the outcome I was expecting for at all so far although I suppose that’s never how it really goes.
3 · Reply
BillionerOfKing
BillionerOfKing Jun. 25 at 6:15 PM
$ROIV Current Stock Price: $33.90 Contracts to trade: $34.0 ROIV Jul 17 2026 Call Entry: $0.15 Exit: $0.22 ROI: 49% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
mj6534
mj6534 Jun. 24 at 6:33 PM
$ABUS I’ve watch $ROIV go from 3$ to now $34 since 2022 meanwhile we are in the same spot basically lol
2 · Reply
WAJeff
WAJeff Jun. 24 at 4:00 PM
$ROIV Remember how Vivek sold shares to fund his idiotic presidential campaign and then got muscled out of DOGE by Elon? He can’t even grift well. Staying out of politics would have worked out better for him.
1 · Reply
Alfalcon
Alfalcon Jun. 24 at 3:50 PM
$ROIV
0 · Reply
Joe_Mama
Joe_Mama Jun. 23 at 11:59 PM
$ROIV On a day like today = I’ll take it!
3 · Reply
Alfalcon
Alfalcon Jun. 23 at 6:59 PM
$ROIV LFG
0 · Reply
5htc2
5htc2 Jun. 23 at 6:56 PM
$ROIV what is with the pop?
0 · Reply
SpaceCityKid
SpaceCityKid Jun. 22 at 3:35 PM
$ROIV IMVT breaks out and ABUS getting closer. ROIV has a lot of + things happening
0 · Reply
Joe_Mama
Joe_Mama Jun. 12 at 9:38 PM
$ROIV Something is coming
5 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 10 at 12:14 PM
$ROIV Excellent article that nails exactly where ROIV stands right now. So if you want to update your ROIV knowledge or get acquainted with ROIV, this is a must read. https://everyticker.com/quote/ROIV/analysis/roivant-s-capital-fortress-how-4-3b-in-cash-and-a-three-pronged-pipeline-create-asymmetric-upside-nasdaq-roiv
1 · Reply
LM_Johanssen
LM_Johanssen Jun. 9 at 6:45 PM
$ROIV
0 · Reply